title: Eloctate for hemophilia A.
abstract: Eloctate, a recombinant factor VIII Fc fusion protein with an extended half-life, was effective in preventing and controlling bleeding in patients with severe hemophilia A. Compared to other currently available factor VIII products, Eloctate's extended half-life reduces the number of doses required for routine prophylaxis, which could improve adherence. Eloctate has not been associated with formation of neutralizing antibodies, but it was not studied in previously untreated patients with severe hemophilia A, who have a higher risk of this complication. Like other recombinant factor VIII products, Eloctate is very expensive.
mesh_terms: D000818:Animals; D002986:Clinical Trials as Topic / Q000379:methods; D005169:Factor VIII / Q000378:metabolism / Q000627:therapeutic use*; D006207:Half-Life; D006467:Hemophilia A / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006470:Hemorrhage / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000378:metabolism / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000378:metabolism / Q000627:therapeutic use*
chemical_list: D007141:Immunoglobulin Fc Fragments; D011993:Recombinant Fusion Proteins; C587014:factor VIII-Fc fusion protein; D005169:Factor VIII